

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

REMARKS

Upon entry of the foregoing amendment, claims 60-70 are pending in the application. Claims 60-70 are newly added. Claims 1-59 have been cancelled without prejudice or disclaimer.

Support for new claim 60 is found as follows:

for multiple antigens, on page 7, line 8, for example;
for separate application of antigen and adjuvant, page 26, lines 20-22, for example;
for application of a formulation to more than one site, page 63, Example 13; page 8, lines 3-5;
and for using multiple applications on page 8, lines 3-5, for example;
for concurrent use of penetration enhancer compounds, on page 14, lines 6-7, for example; and,
for concurrent use of penetration compounds and techniques, on page 14, lines 17-20; and,
elsewhere throughout the specification.

Support for new claim 61 is found, for example, on page 11, line 3 through page 12, line 12; and, elsewhere throughout the specification.

Support for new claim 62 is found, for example, on page 14, lines 6-16; original claims 7, 8, 9, 11 and 14; and, elsewhere throughout the specification.

Support for new claim 63 is found, for example, on page 70, lines 29-30; and, elsewhere throughout the specification.

Support for new claim 64 is found, for example, on page 7, lines 29-30 (“a device for physical penetration enhancement may be included in a patch”); and, elsewhere throughout the specification.

Support for new claim 65 is found, for example, as follows:

for propellant devices, devices comprising tines, devices comprising microneedles (page 12,

lines 14-15);
for devices comprising a tyne disk (page 12, lines 17-21);
for devices for adhesive tape stripping (page 46, lines 24-25);
for gas powered guns (page 46, line 24);
for abrasive devices (Example 5, page 46; Example 6, page 48);
for electroporation devices, ultrasound devices and iontophoretic devices (page 12, lines 13-14);
and, elsewhere throughout the specification.

Support for new claim 66 is found, for example, on page 12, lines 23-24; and, elsewhere throughout the specification.

Support for new claim 67 is found, for example, on page 12, lines 20-21; and, elsewhere throughout the specification.

Support for new claim 68 is found, for example, for bAREs, on page 26, line 31; for a binding B subunit of a bARE, on page 28, lines 9-10; for a toxoid of a bARE, on page 28, line 32 through page 29, line 21; and, elsewhere throughout the specification.

Support for new claim 69 is found, for example, on page 9, lines 24-26; and, elsewhere throughout the specification.

Support for new claim 70 is found, for example, on page 9, lines 15-18; in original claims 47-49; and, elsewhere throughout the specification.

It is believed that no new matter has been introduced by this Preliminary Amendment.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, including any required

extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **Constructive Petition for Extension of Time** in accordance with 37 C.F.R. § 1.136(a)(3).

It is believed the application is in condition for examination on the merits and such is respectfully requested. If, in the opinion of the Examiner, an interview would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the telephone number provided below.

Dated: **March 3, 2004**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Erich E. Veitenheimer
Registration No. 40,420

contralateral

immunized arm

10


10



Control lateral



Immunized Arm




2a



2b



2c



2d